Nanolek Pharmaceutical Company, a member of BIOPROM, has launched the country's first vaccine production plant against human papillomavirus in the Kirov region.
The total investment is 7.5 billion rubles, of which 950 million were provided by the Industrial Development Fund for the purchase of equipment.
The production is organized according to the full cycle. The first site produces 600 thousand doses per year, after the launch of the second — more than 3 million doses, which will fully cover the needs of domestic healthcare and enter the international market.
The Cegardex vaccine protects against HPV types that cause cervical cancer and may be included in the National Vaccination Calendar by 2026.
"The development and organization of HPV vaccine production is an important step towards achieving Russia's drug independence and technological sovereignty in the field of immunoprophylaxis. So far, only foreign drugs have been used in the country to prevent HPV," the Nanolek press service said.
The total investment is 7.5 billion rubles, of which 950 million were provided by the Industrial Development Fund for the purchase of equipment.
The production is organized according to the full cycle. The first site produces 600 thousand doses per year, after the launch of the second — more than 3 million doses, which will fully cover the needs of domestic healthcare and enter the international market.
The Cegardex vaccine protects against HPV types that cause cervical cancer and may be included in the National Vaccination Calendar by 2026.
"The development and organization of HPV vaccine production is an important step towards achieving Russia's drug independence and technological sovereignty in the field of immunoprophylaxis. So far, only foreign drugs have been used in the country to prevent HPV," the Nanolek press service said.